Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma (OncoDaily) - Sep 17, 2026 - "The investigator-initiated, multicenter phase I study, CA209-731/NCT03143270, included patients with unresectable, liver-limited HCC who were not candidates for curative resection or liver transplantation....Among the 19 patients, the ORR was 21% (95% CI, 6%-44%), with four patients achieving a partial response. Stable disease was observed in 11 patients (58%), progressive disease in three patients (16%) and one patient was not assessable for response. Median PFS was 5.9 months (95% CI, 3.6-23 months), while median OS was 23 months (95% CI, 19-62 months). Estimated OS rates were 68% at 12 months and 46% at 24 months. Estimated PFS rates were 23% at 12 months and 8.5% at 24 months."
P1 data • Hepatocellular Cancer
|